RAJAF
TFA Therapeutics, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- TrendRANGE
0% above its 50-day average. New closing low $9.18 on Oct 23.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
SecBot reports
4 filings · 0 bullish · 2 bearish · 2 neutral- BEARISH 6-KSep 2, 2026
TFA Therapeutics disclosed an offshore private placement of up to 5,952,381 ordinary shares at…
Monitor for subsequent closings and total proceeds raised — the company's ability to attract capital is a key survival signal given the going-concern warning. The 20% discount to reference valuation…
- NEUTRAL 6-KJul 27, 2026
TFA Therapeutics, Inc. (f/k/a Cordyceps Sunshine Biotech Holdings Co., Ltd.) filed a 6-K reporting…
The name change is administrative and does not alter the company's fundamentals. Monitor the next 10-Q or 20-F for any improvement in the going-concern status or remediation of internal control…
- NEUTRAL 6-KJun 25, 2026
Cordyceps Sunshine Biotech entered into a Cooperation and Development Agreement with Pet Sunshine…
This agreement provides Cordyceps Sunshine with a pipeline asset but no near-term cash infusion. Monitor for any subsequent capital raising or milestone announcements to gauge execution progress…
- BEARISH 20-FMay 15, 2026
Cordyceps Sunshine Biotech Holdings Co., Ltd. filed its Form 20-F annual report for FY2025…
This micro-cap OTC stock faces existential going-concern risk with only $3,199 in cash and negative working capital of $4.19M. The company relies entirely on related-party borrowings for survival…
All RAJAF filing & press-release reports (4)
- 6-K reportSep 2, 2026
- 6-K reportJul 27, 2026
- 6-K reportJun 25, 2026
- 20-F reportMay 15, 2026